A Phase I/II Study to Assess the Safety and Tolerability of the Combination of Oral ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Press/Media

Period18 Apr 2024

Media coverage

1

Media coverage

  • TitleA Phase I/II Study to Assess the Safety and Tolerability of the Combination of Oral ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
    Media name/outletVaccine Daily
    Country/TerritoryUnited States
    Date18/04/24
    PersonsSamir Parekh
View all 1
View less